Exploratory Evaluation of Novel Investigational Eye Movement Biomarkers to Track Ofatumumab Treatment Response in Canadian Patients With Active Relapsing-Remitting Multiple Sclerosis (ELIOS)

Novartis Pharmaceuticals14 个研究点分布在 1 个国家目标入组 224 人2024年11月27日

适应症Relapsing Remitting Multiple Sclerosis (RRMS)

概览

阶段: 4 期
干预措施: 未指定
疾病 / 适应症: Relapsing Remitting Multiple Sclerosis (RRMS)
发起方: Novartis Pharmaceuticals
入组人数: 224
试验地点: 14
主要终点: 1- Change Eye Movement Biomarkers (EMB)
状态: 招募中
最后更新: 上个月

概览研究者入排标准结局指标研究点相似试验

概览

简要总结

The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

注册库

clinicaltrials.gov

开始日期

2024年11月27日

结束日期

2027年11月30日

最后更新

上个月

研究类型

Interventional

研究设计

Single Group

性别

All

研究者

发起方

Novartis Pharmaceuticals

责任方

Sponsor

入排标准

入选标准

•Patients eligible for inclusion in the study must fulfill all of the following criteria:
•Adult patients who are prescribed ofatumumab as part of routine clinical care as per the PM but who have not yet received their first dose. The decision to prescribe ofatumumab must be made prior to and independent of study participation.
•Patients or their legally authorized representatives who sign the Institutional Review Boards/Independent Ethics Committee (IRB/IEC)-approved informed consent form.
•Patients who meet the EDSS score range of 0 up to 7 at the time of screening and enrollment for ofatumumab treatment.
•Patients with a diagnosis of active RRMS according to the 2017 Revised McDonald criteria
•Patients who can provide blood samples.
•Patients who can understand written and spoken Canadian English or French.
•Patients who have sufficient corrected visual acuity to allow for accurate reading of the on-screen visual task instructions, in the judgement of the Investigator. If a relapse temporarily affects a patient's corrected visual acuity, the Baseline Visit may be postponed until the patient can accurately read the on-screen visual task instructions, if deemed acceptable by the Investigator and the patient.
•Patients with a confirmed diagnosis of MS with no signs of progressive increase in physical disability independent of relapse activity within the past six months, as assessed by a physician.

排除标准

•In order to ensure that the study population will be representative of all eligible patients, no additional exclusions may be applied by the Investigator. Patients meeting any of the following criteria are not eligible for inclusion in this study:
•Patients with primary progressive MS, secondary progressive MS without disease activity, clinically isolated syndrome, or radiologically isolated syndrome.
•Any disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures.
•Pregnant or nursing (lactating) women.
•Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception while taking ofatumumab and for six months after stopping medication. Effective contraception methods include:
•Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
•Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks prior to enrollment. In case of oophorectomy alone, the reproductive status of the woman must be confirmed by follow-up hormone level assessment
•Male sterilization at least six months prior to enrollment. For female participants on the study, the vasectomized male partner should be the sole partner for that participant
•Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%) such as hormone vaginal ring or transdermal hormone contraception
•Use of barrier methods of contraception (male or female condom, occlusive cap, diaphragm or cervical/vault caps)

结局指标

主要结局

1- Change Eye Movement Biomarkers (EMB)

时间窗: 6 months from baseline

Change in subtle eye movement anomalies referred to as Eye Movement Biomarkers (EMBs). EMB are derived from composite scores of various Eye Movement metrics. Results stratified by patients experiencing a clinically meaningful change (CMC) in at least one traditional MS outcome (CMCp) or no CMC in all traditional MS outcomes (CMCs/i) at 24 months (or at the time of ofatumumab discontinuation and treated with ofatumumab for at least 12 months)

次要结局

1a. Change in EMB(3,12 and 24 months from Baseline)
1b. Change in EMB trajectories(3-, 6-, 12-, and 24-months)
2a. Change in Annual Relapse Rate (ARR)(12 and 24 months from baseline)
2b. Change in patient disability measured by Expanded Disability Status Scale EDSS(3,6,12,24 months from baseline)
2b. Change in patient disability measured by Timed 25-foot walk test (T25-FW)(3,6,12,24 months from baseline)
2b. Change in patient disability measured by the 9-hole peg test (9-HPT)(3,6,12,24 months from baseline)
2c. Change in objective measures of cognitive impairment as measured by the Symbol Digit Modalities Test (SDMT)(3,6,12,24 months from baseline)
2c. Change in objective measures of cognitive impairment as measured by the Brief Visuospatial Memory Test (BVMT-R)(3,6,12,24 months from baseline)
2c. Change in objective measures of cognitive impairment as measured by the Rey Auditory Verbal Learning Test (RAVLT)(3,6,12,24 months from baseline)
3a. Association between EMB and annual relapse rate (AAR)(12 and 24 months)
3b. Association of EMBs and objective measures of disability - EDSS, T25-FW, and 9-HPT(Up to 24 months)
3c. Association of EMBs and objective measures of cognitive impairment - SDMT(Up to 24 months)
3c. Association of EMBs and objective measures of cognitive impairment - BVMT-R, and RAVLT(Up to 24 months)
4. Change in serum Neurofilament light Chain (sNfL)(3,6,12,24 months from baseline)
5a. Change in patient-reported physical and psychological impact of MS disease as measured by the Multiple Sclerosis impact scale-29 version 2 (MSIS-29v2)(3,6,12,24 months from baseline)
5b. Baseline assessment and change in patient-reported depression as measured by the Beck depression inventory-II (BDI-II)(3,6,12,24 months from baseline)
5c. Change in patient-reported cognitive impairment as measured by the MS neuropsychology questionnaire (MSNQ)(3,6,12,24 months from baseline)
5d. Change in patient-reported mobility as measured by the MS walking scale-12 version 1 (MSWS-12v1)(3,6,12,24 months from baseline)
6. Incidence of treatment emergent adverse events and serious adverse events(24 months)